Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
SMAD4 mutant
|
colorectal cancer
|
no benefit |
Cetuximab
|
Clinical Study |
Actionable |
In a clinical study, Chinese metastatic colorectal cancer patients harboring either a SMAD4 mutation or NF1 mutation did not respond to treatment with Erbitux (cetuximab) and showed a shorter progression-free survival compared to patients with wild-type SMAD4 or wild-type NF1 (PMID: 29703253).
|
29703253
|